Status:
COMPLETED
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
Lead Sponsor:
Vir Biotechnology, Inc.
Collaborating Sponsors:
Alnylam Pharmaceuticals
Conditions:
Chronic Hepatitis B
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety...
Eligibility Criteria
Inclusion
- Male or female of ages 18 - 65
- Chronic HBV infection for \>/= 6 months
Exclusion
- Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation
- Significant fibrosis or cirrhosis
- History or evidence of drug or alcohol abuse
- History of intolerance to SC injection
- History of chronic liver disease from any cause other than chronic HBV infection
- History of hepatic decompensation
- Any prior receipt of an interferon product
Key Trial Info
Start Date :
July 3 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 25 2024
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT04412863
Start Date
July 3 2020
End Date
March 25 2024
Last Update
September 19 2024
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigative Site
Birtinya, Queensland, Australia, 4575
2
Investigative Site
Fitzroy, Victoria, Australia, 3168
3
Investigative site
Hong Kong, Hong Kong
4
Investigative Site
Batu Caves, Malaysia, 68100